Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

Abstract

Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: PTX and BB rescue Ts65Dn performance in the novel object recognition task.
Figure 2: PTZ elicits long-lasting cognitive improvement in Ts65Dn mice.
Figure 3: PTZ rescues LTP at medial perforant path–granule cell synapses in Ts65Dn mice.

References

  1. Seregaza, Z., Roubertoux, P.L., Jamon, M. & Soumireu-Mourat, B. Behav. Genet. 36, 387–404 (2006).

    Article  Google Scholar 

  2. Holtzman, D.M. et al. Proc. Natl. Acad. Sci. USA 93, 13333–13338 (1996).

    CAS  Article  Google Scholar 

  3. Kurt, M.A., Davies, D.C., Kidd, M., Dierssen, M. & Florez, J. Brain Res. 858, 191–197 (2000).

    CAS  Article  Google Scholar 

  4. Belichenko, P.V. et al. J. Comp. Neurol. 480, 281–298 (2004).

    Article  Google Scholar 

  5. Hanson, J.E., Blank, M., Valenzuela, R.A., Garner, C.C. & Madison, D.V. J. Physiol. (Lond.) (in the press).

  6. Kleschevnikov, A.M. et al. J. Neurosci. 24, 8153–8160 (2004).

    CAS  Article  Google Scholar 

  7. Costa, A.C.S. & Grybko, M.J. Neurosci. Lett. 382, 317–322 (2005).

    CAS  Article  Google Scholar 

  8. Nadel, L. Genes Brain Behav. 2, 156–166 (2003).

    CAS  Article  Google Scholar 

  9. McGaugh, J.L. Science 153, 1351–1358 (1966).

    CAS  Article  Google Scholar 

  10. Ivic, L. et al. J. Biol. Chem. 278, 49279–49285 (2003).

    CAS  Article  Google Scholar 

  11. Levy, S. J. Am. Med. Assoc. 153, 1260–1265 (1953).

    CAS  Article  Google Scholar 

  12. Landfield, P.W., Baskin, R.K. & Pitler, T.A. Science 214, 581–584 (1981).

    CAS  Article  Google Scholar 

  13. Gerlai, R. Behav. Brain Res. 95, 91–101 (1998).

    CAS  Article  Google Scholar 

  14. Whitlock, J.R., Heynen, A.J., Shuler, M.G. & Bear, M.F. Science 313, 1093–1097 (2006).

    CAS  Article  Google Scholar 

  15. Pastalkova, E. et al. Science 313, 1141–1144 (2006).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank the Down Syndrome Research and Treatment Foundation (DSRTF), the Hillblom Foundation, the US National Science Foundation (NSF), the US National Institute of Health (NIH), Jax West Laboratories, the Stanford Down Syndrome Center and W.C. Mobley for their support.

Author information

Authors and Affiliations

Authors

Contributions

F.F. designed and executed all behavioral experiments with the assistance of E.Z. and J.N. W.M. performed all of the electrophysiology experiments. M.B. provided technical expertise in breeding and genotyping. F.F., C.C.G., W.M. and R.C.M. wrote and edited the manuscript.

Corresponding author

Correspondence to Craig C Garner.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Ts65Dn mice exhibit declarative memory problems, but intact procedural learning. (PDF 101 kb)

Supplementary Fig. 2

Chronic but not acute administration of picrotoxin (PTX) normalizes Ts65Dn performance in the novel object recognition task. (PDF 94 kb)

Supplementary Table 1

Tabulated discrimination indices (DI's) in the novel object recognition task. (PDF 148 kb)

Supplementary Table 2

Picrotoxin (PTX), bilobalide (BB) and pentylenetetrazole (PTZ) do not affect exploration times in the novel object recognition task. (PDF 148 kb)

Supplementary Table 3

Tabulated alternation percentages (%) in the spontaneous alternation task. (PDF 154 kb)

Supplementary Table 4

Pentylenetetrazole (PTZ) does not affect arm entries in the spontaneous alternation task. (PDF 147 kb)

Supplementary Discussion

Potential utility of non-competitive GABAA receptor antagonists for the treatment of cognitive impairment in Down syndrome. (PDF 97 kb)

Supplementary Methods (PDF 104 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fernandez, F., Morishita, W., Zuniga, E. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10, 411–413 (2007). https://doi.org/10.1038/nn1860

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nn1860

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing